ArticleNeurosurgical review2025
Effect of fludrocortisone in the management of hyponatremia after aneurysmal subarachnoid hemorrhage.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) is associated with significant morbidity, particularly related to delayed cerebral ischemia (DCI). Hyponatremia, defined as a serum sodium level < 135 mmol/l, is a common complication of aSAH and is associated with the development of DCI. Fludrocortisone is used to decrease natriuresis and improve hyponatremia, but has failed to demonstrate a reduction in the frequency of cerebral vasospasm or DCI. Using the ProReSHA database, we retrospectively analyzed the impact of fludrocortisone on the development of DCI in patients hospitalized in neurocritical care unit after aSAH and presenting hyponatremia. Two hundred sixteen patients were included, 88 in the fludrocortisone group and 128 in the control group. DCI occurred in 35 (39.8%) patients in the fludrocortisone group and 34 (26.6%) in the control group (p = 0.058). Hyponatremia was significantly deeper in the fludrocortisone group than in the control group (median [interquartile range]: 130 [128-131] vs. 132 [131-133] mmol/l; p < 0.001), and lasted longer (6.0 [4.0-8.3] vs. 3.0 [2.0-5.0] days; p < 0.001). An ancillary analysis stratified according to the etiology of hyponatremia (cerebral salt wasting syndrome or syndrome of inappropriate secretion of antidiuretic hormone) also found no significant difference regarding DCI occurrence (33.3% vs. 44.6%; p = 0.238) but a significantly lower natriuresis in the cerebral salt wasting syndrome group (225 [187-308] vs. 293 [253-359] mmol/d; p = 0.01). Fludrocortisone did not prevent the development of DCI in patients admitted to a neurocritical care unit for an aneurysmal subarachnoid hemorrhage and presenting with hyponatremia. Effect of fludrocortisone in the management of hyponatremia after aneurysmal subarachnoid hemorrhage.
Indexed as
Identifiers
41003795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.